Sarepta Therapeutics (NASDAQ:SRPT) Earns Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $128.00 price objective on the biotechnology company’s stock.

Other research analysts have also issued research reports about the company. Royal Bank of Canada raised their target price on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an outperform rating in a report on Thursday, February 29th. Barclays raised their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the company an overweight rating in a report on Thursday, February 29th. BMO Capital Markets started coverage on Sarepta Therapeutics in a report on Wednesday, January 31st. They issued an outperform rating and a $170.00 target price on the stock. Needham & Company LLC reaffirmed a buy rating and set a $166.00 price target on shares of Sarepta Therapeutics in a research report on Thursday. Finally, UBS Group increased their price target on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a buy rating in a research report on Friday, March 1st. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of Moderate Buy and a consensus price target of $160.60.

Sarepta Therapeutics Stock Up 2.3 %

Shares of NASDAQ:SRPT opened at $133.66 on Thursday. The business’s 50 day simple moving average is $125.63 and its two-hundred day simple moving average is $110.74. The firm has a market cap of $12.63 billion, a P/E ratio of 1,215.09 and a beta of 0.95. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.84. The business had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company’s quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.44) earnings per share. As a group, research analysts forecast that Sarepta Therapeutics will post 2.23 EPS for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In related news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Ian Michael Estepan sold 1,200 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now owns 39,114 shares in the company, valued at approximately $5,018,326.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,096 shares of company stock worth $2,739,419. Company insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 87 shares during the period. Vanguard Capital Wealth Advisors grew its holdings in shares of Sarepta Therapeutics by 3.8% during the 4th quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after acquiring an additional 90 shares during the period. DMC Group LLC boosted its position in shares of Sarepta Therapeutics by 2.9% in the 3rd quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock worth $400,000 after purchasing an additional 93 shares in the last quarter. Riggs Asset Managment Co. Inc. boosted its position in shares of Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares in the last quarter. Finally, WCM Investment Management LLC boosted its position in shares of Sarepta Therapeutics by 2.3% in the 1st quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock worth $813,000 after purchasing an additional 142 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.